J&J therapy shows strong survival benefit in prostate cancer patients |
Johnson & Johnson's prostate cancer drug Erleada, reportedly used alongside standard home-blocking therapy before and after prostate surgery significantly enhances the chances of eliminating the cancer and reduces the risk of death or disease progression.
While patients taking the combination regimen were found to be nine times more likely to have little to no detectable cancer in the........